Glossary

Plain-language definitions of the terms that come up in Parkinson's research. Any underlined word inside an issue can be tapped to see its meaning without leaving the page.

A

Alpha-synuclein: A protein that every human brain makes. In Parkinson's disease it misfolds into the wrong shape and clumps together inside nerve cells. Most researchers now think these clumps are central to how the disease starts and spreads, which is why so many experimental treatments try to target this one protein.

B

Biomarker: Something measurable in the body — in blood, spinal fluid, skin, or on a scan — that tells you about a disease. A good biomarker can show whether someone has a condition, how far it has advanced, or whether a drug is working. Parkinson's has historically lacked good biomarkers, which has made trials slow and expensive.
Blinding: Keeping people in a trial from knowing who got the real treatment and who got the placebo. In a double-blind trial neither the participants nor the doctors assessing them know. This matters enormously in Parkinson's, because expectation alone can genuinely improve movement for a while.

C

Cerebrospinal fluid: The clear liquid that surrounds the brain and spinal cord, collected through a lumbar puncture in the lower back. Because it is in direct contact with the brain, it carries chemical signals that blood does not, which makes it valuable for research even though collecting it is uncomfortable.
Cohort study: A study that follows a defined group of people over time and observes what happens, without assigning anyone to a treatment. Cohort studies are excellent for spotting patterns and generating ideas, but they cannot prove that one thing caused another.
Confidence interval: The range of values that the true answer is likely to fall within, given the data collected. A narrow interval means the estimate is precise; a wide one means the study could not pin the answer down. Confidence intervals are usually more informative than a single headline number.

D

DAT scan: A brain scan that shows how much dopamine-handling machinery survives in a person's brain. It is used mainly to distinguish Parkinson's from conditions that look similar, such as essential tremor. It confirms dopamine cell loss but does not, on its own, say which disease caused it.
Disease-modifying treatment: A treatment that slows, stops, or reverses the underlying damage of a disease rather than just easing the symptoms. No disease-modifying treatment for Parkinson's has yet been proven to work, and finding one is the central goal of most current research.
Dopamine: A chemical messenger that nerve cells use to communicate. Among many other jobs, it lets the brain produce smooth, well-timed movement. Parkinson's symptoms appear as the cells that make dopamine die off, and most current medicines work by replacing or mimicking it.
Drug repurposing: Testing a medicine already approved for one condition to see whether it helps with another. Because the drug's safety is already established in large numbers of people, repurposing can move faster and cost far less than developing something new from scratch.

E

Effect size: How big a difference a treatment actually made, as opposed to whether the difference was statistically detectable. A result can be statistically solid and still too small for a patient to notice, which is why effect size deserves as much attention as the p-value.
Expression of concern: A public notice a journal attaches to a paper when a serious question has been raised about it but the investigation is not finished. It is not a retraction and it does not mean the findings are wrong; it means readers should know the paper is under review before relying on it. If the concern is resolved the notice is withdrawn, and if it is not the paper may be corrected or retracted.

G

GBA1: A gene that, when altered, is one of the most common genetic risk factors for Parkinson's. It carries instructions for an enzyme that helps cells clear out waste, including misfolded alpha-synuclein. People with GBA1 variants tend to develop the disease somewhat earlier and progress somewhat faster.
GLP-1 receptor agonist: A class of drug originally developed for type 2 diabetes and now widely used for weight loss, including semaglutide and exenatide. They also act on receptors in the brain, which is why researchers have spent more than a decade testing whether they might protect nerve cells in Parkinson's.
Good clinical practice: The international rules governing how clinical trials must be run: how consent is taken, how data is recorded and checked, and who is accountable for each step. Regulators inspect trial sites against these rules. Findings are graded, and a "critical" finding means a problem serious enough to put participants' rights or the reliability of the data in question.

L

Levodopa: The main medicine for Parkinson's, in use since the late 1960s. The brain converts it into dopamine, which restores movement remarkably well, particularly in the early years. It treats symptoms only — it does not slow the underlying loss of nerve cells.
Lewy body: A dense clump of protein, mostly alpha-synuclein, found inside nerve cells in the brains of people with Parkinson's. They were first described in 1912 and remain one of the defining features pathologists look for after death.
LRRK2: A gene whose variants are the most common known genetic cause of inherited Parkinson's, and a major drug target. Several companies are testing drugs that quiet down overactive LRRK2, on the theory that this could slow the disease in people who carry these variants — and perhaps in others too.

M

MDS-UPDRS: The standard rating scale used to measure Parkinson's severity, covering daily experiences, motor examination, and complications of treatment. Higher scores mean more severe disease. Almost every clinical trial reports its results using this scale, so it is worth recognising the name.
Meta-analysis: A study of studies. Researchers pool the results of many separate trials to get a more reliable overall answer than any one of them could give. A meta-analysis is only as good as the studies it draws on.
Motor symptoms: The movement-related features of Parkinson's: slowness, stiffness, tremor, and problems with balance and walking. These are what most people picture when they think of the condition, and what current medicines treat best.

N

Neuroprotection: Protecting nerve cells from dying. A neuroprotective treatment for Parkinson's would keep the remaining dopamine cells alive for longer. Many candidates have looked promising in animals and then failed in people.
Non-motor symptoms: Everything about Parkinson's that is not movement: constipation, loss of smell, disrupted sleep, low blood pressure on standing, anxiety, depression, pain, and changes in thinking and memory. Patients often rate these as having a greater effect on daily life than the movement symptoms, and they are less well treated.

O

Open-label: A study in which everyone knows who is getting the treatment. Open-label studies are useful for checking safety and practicality, but their results on symptoms should be treated cautiously, because knowing you are on a drug can change how you feel and how an assessor scores you.

P

P-value: A number describing how likely it is that a result this striking could have appeared by chance alone if the treatment did nothing. Below 0.05 is the traditional threshold for calling a result statistically significant, but that cut-off is a convention, not a law of nature.
Parkinson's disease: A progressive condition in which nerve cells that produce dopamine gradually die, mostly in a small brain region called the substantia nigra. It causes slowness, stiffness, tremor and balance problems, along with a wide range of non-movement symptoms. It affects roughly one in a hundred people over 60, and there is currently no treatment that stops or reverses it.
Peer review: The process where independent experts examine a study before a journal publishes it, checking the methods and conclusions. It filters out a good deal of weak work, but it is not a guarantee of truth — plenty of peer-reviewed findings later fail to hold up.
Phase 2 trial: A mid-stage trial, usually a few dozen to a few hundred people, designed to look for early signs that a treatment works and to refine the dose. Encouraging phase 2 results are genuinely common; most of them do not survive a phase 3 trial.
Phase 3 trial: A large, long, rigorous trial — often hundreds of participants across many hospitals — designed to give a definitive answer about whether a treatment works. This is the evidence regulators require before approving a drug.
Placebo: A dummy treatment with no active ingredient, given so that its effect can be compared against the real thing. Parkinson's is notable for unusually strong placebo responses: the expectation of benefit can itself trigger dopamine release, producing real, measurable improvement.
Preprint: A study posted publicly by its authors before peer review. Preprints spread findings quickly, which is valuable, but they have not yet been checked by independent experts, so their claims deserve extra caution.
Primary endpoint: The single main question a trial commits to answering, chosen before the trial starts. If a trial misses its primary endpoint, it has failed, regardless of how many other encouraging numbers appear elsewhere in the results.
Prodromal: The stage before a disease is diagnosable, when subtle changes have begun but the defining symptoms have not appeared. The Parkinson's prodrome can last a decade or more and may involve loss of smell, constipation, and acting out dreams during sleep.

R

Randomised controlled trial: A study in which participants are assigned to treatment or comparison groups purely by chance. Randomising evens out the differences between groups, which is what makes this design the most reliable way to find out whether a treatment truly works.
REM sleep behaviour disorder: A sleep condition in which people physically act out their dreams, sometimes violently, because the paralysis that normally accompanies dreaming fails. It is one of the strongest known warning signs of future Parkinson's or a related condition, often appearing many years ahead of any movement symptoms.

S

Seed amplification assay: A laboratory test that takes a sample from a person, adds normal alpha-synuclein protein, and sees whether anything in that sample causes the added protein to misfold and clump. If it does, misfolded alpha-synuclein was present. The test amplifies a tiny signal into a readable one, much as a PCR test does for viral genetic material.
Statistical significance: A finding is called statistically significant when it is unlikely to have arisen by chance. It says nothing about whether the finding is large, useful, or meaningful to a patient — a common and consequential misunderstanding.
Substantia nigra: A small, dark-pigmented area deep in the brain that houses most of the dopamine-producing cells lost in Parkinson's. Its name is Latin for "black substance". By the time motor symptoms appear, a substantial share of these cells is already gone.
Symptomatic treatment: A treatment that eases symptoms without changing the course of the disease. Levodopa is the classic example: it can transform how someone feels and moves, while the underlying cell loss continues.